Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thymic stromal lymphopoietin deficiency attenuates experimental autoimmune encephalomyelitis.

Clinical and experimental immunology·2015

Same author

Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia.

Leukemia research·2009

Same author

Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.

Skin pharmacology and physiology·2007

Same author

Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2007

Same author

The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.

Skin pharmacology and physiology·2006

Same author

Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients.

Tissue antigens·2006

Same journal

Beyond pathogen recognition: C-type lectin receptors in microbiota regulation.

Mucosal immunology·2026

Same journal

Mucin degradation by Akkermansia muciniphila promotes Alistipes-dependent tryptophan metabolism and Th17-driven autoimmunity.

Mucosal immunology·2026

Same journal

Helminths hijack the TGFβ receptor to promote a pro-regenerative program in the intestinal stem cell compartment.

Mucosal immunology·2026

Same journal

Bioinformatics roadmap for characterizing the gut microbiome to study its interactions and associations with the gut mucosal immune system.

Mucosal immunology·2026

Same journal

4-1BBL on monocyte lineage cells rather than on classical dendritic cells drives CD8<sup>+</sup> T cell accumulation in the respiratory tract and protects from severe respiratory influenza infection.

Mucosal immunology·2026

Same journal

BAMBI: A novel regulator of intestinal epithelial integrity in the control of colitis and colon cancer progression.

Mucosal immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 4, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Soluble CD83 ameliorates experimental colitis in mice.

J Eckhardt¹, S Kreiser¹, M Döbbeler¹

¹Department of Immune Modulation at the Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.

Mucosal Immunology

|January 16, 2014

Summary

This summary is machine-generated.

Soluble CD83 (sCD83) effectively treats inflammatory bowel disease (IBD) in mice by reducing inflammation and mortality. This novel therapeutic approach shows promise for IBD treatment by modulating immune responses.

More Related Videos

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

Related Experiment Videos

Last Updated: May 4, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

Area of Science:

Immunology
Gastroenterology
Molecular Biology

Background:

Inflammatory bowel diseases (IBD) involve immune dysregulation, with current therapies having limitations.
Soluble CD83 (sCD83) exhibits immunosuppressive properties, but its role in IBD is unexplored.

Purpose of the Study:

To investigate the expression and function of CD83 in a murine colitis model.
To evaluate the therapeutic potential of sCD83 in ameliorating experimental colitis.

Main Methods:

Induced colitis in mice and analyzed CD83 expression in leukocytes.
Administered sCD83 and assessed clinical symptoms, mortality, and inflammatory markers.
Investigated the role of indolamine 2,3-dioxygenase (IDO) in sCD83's protective effects.

Main Results:

CD83 expression was upregulated in leukocytes during colitis.
sCD83 treatment significantly reduced disease severity, mortality, and inflammatory cytokine levels.
sCD83 inhibited the infiltration of macrophages and granulocytes into colonic tissue.
sCD83-induced IDO expression was crucial for its therapeutic efficacy.

Conclusions:

sCD83 demonstrates significant therapeutic potential for inflammatory bowel disease.
sCD83 ameliorates colitis by suppressing key inflammatory pathways, potentially via IDO induction.